CTLA4 and colorectal carcinoma: Conversely, this mechanism may underlie the improved outcomes seen with combination immunotherapy, as dual PD-(L)1 and CTLA-4 blockade can achieve ORRs of up to 20% in pMMR CRC patients, supporting the rationale for targeting multiple immune-regulatory axes [43].